Mismatch-Repair Deficiency Confers Sensitivity to Checkpoint Blockade [Clinical Trials]

PD-1 blockade with pembrolizumab achieves responses in 53% of patients with MMR-deficient tumors.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: Clinical Trials Source Type: research